≥25个脑转移瘤立体定向放射外科治疗中的海马保护
该前瞻性登记研究分析了89例接受立体定向放射外科(SRS)治疗的≥25个脑转移瘤患者,通过5 mm扩边构建海马回避区(HA区),汇总各次治疗剂量计算海马剂量。结果显示,即使肿瘤负荷高且部分肿瘤位于HA区,SRS仍可实现海马保护;但HA区内肿瘤患者的海马剂量更高,且超过半数可评估患者最终出现海马旁转移。
要点
- ≥25个脑转移瘤患者接受SRS时,海马剂量与肿瘤数目和体积显著相关
- HA区内肿瘤患者的海马剂量高于无HA区肿瘤者,但SRS仍可实现海马保护
- 57%可评估患者存在HA区肿瘤,提示海马旁转移常见
核心结论
- 对于颅内病灶负荷高且存在HA区肿瘤的患者,SRS仍能实现海马保护。
- HA区内肿瘤患者的海马剂量更高,且超过半数可评估患者最终出现海马旁转移。
研究设计与样本
- 前瞻性登记研究,纳入89例接受SRS治疗的≥25个脑转移瘤患者。
- 在海马5 mm扩边构建HA区,汇总各次治疗剂量计算海马剂量,分析转移瘤相对HA区和海马的分布。
主要发现
- 每例患者中位肿瘤数为33个(范围25-116),中位治疗3次(范围1-12)。
- 全部患者中位双侧海马Dmin(D100)、D40、D50、Dmax、Dmean分别为1.88、3.94、3.62、16.6、3.97 Gy。
- 肿瘤位于HA区外的患者中位双侧海马Dmin、D40、D50、Dmax、Dmean分别为1.43、2.99、2.88、5.64、3.07 Gy。
- 多因素线性回归显示,中位海马D40、D50和Dmin与肿瘤数目和肿瘤体积显著相关(p < 0.001)。
- 3059个治疗肿瘤中83个(2.7%)位于HA区,见于57%可评估患者;38个肿瘤(1.2%)毗邻或累及海马本身。
临床怎么用
- 对≥25个脑转移瘤患者行SRS时,应评估HA区肿瘤分布并尽量保护海马。
- 海马剂量与肿瘤数目和体积相关,肿瘤负荷高者需更关注海马受量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE/OBJECTIVES: To report our dosimetric analysis of the hippocampi (HC) and the incidence of perihippocampal tumor location in patients with ≥25 brain metastases who received stereotactic radiosurgery (SRS) in single or multiple sessions. MATERIALS/METHODS: Analysis of our prospective registry identified 89 patients treated with SRS for ≥25 brain metastases. HC avoidance regions (HA-region) were created on treatment planning MRIs by 5 mm expansion of HC. Doses from each session were summed to calculate HC dose. The distribution of metastases relative to the HA-region and the HC was analyzed. RESULTS: Median number of tumors irradiated per patient was 33 (range 25-116) in a median of 3 (range1-12) sessions. Median bilateral HC Dmin (D100), D40, D50, Dmax, and Dmean (Gy) was 1.88, 3.94, 3.62, 16.6, and 3.97 for all patients, and 1.43, 2.99, 2.88, 5.64, and 3.07 for patients with tumors outside the HA-region. Multivariate linear regression showed that the median HC D40, D50, and Dmin were significantly correlated with the tumor number and tumor volume (p < 0.001). Of the total 3059 treated tumors, 83 (2.7%) were located in the HA-region in 57% evaluable patients; 38 tumors (1.2%) abutted or involved the HC itself. CONCLUSIONS: Hippocampal dose is higher in patients with tumors in the HA-region; however, even for patients with a high burden of intracranial disease and tumors located in the HA-regions, SRS affords hippocampal sparing. This is particularly relevant in light of our finding of eventual perihippocampal metastases in more than half of our patients.
引用
- Kavi A, Gurewitz J, Benjamin CG, et al. Hippocampal sparing in patients receiving radiosurgery for ≥25 brain metastases. Radiother Oncol. 2021. PMID: 34052342. doi:10.1016/j.radonc.2021.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。